Alliancebernstein L.P. maintained its position in ZIOPHARM Oncology Inc (NASDAQ:ZIOP) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 194,519 shares of the biotechnology company’s stock at the end of the first quarter. Alliancebernstein L.P. owned 0.15% of ZIOPHARM Oncology worth $1,233,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Norges Bank purchased a new position in ZIOPHARM Oncology during the fourth quarter worth approximately $5,556,000. Teachers Advisors LLC boosted its position in ZIOPHARM Oncology by 1.9% in the fourth quarter. Teachers Advisors LLC now owns 198,508 shares of the biotechnology company’s stock worth $1,062,000 after buying an additional 3,699 shares during the last quarter. Highbridge Capital Management LLC purchased a new position in ZIOPHARM Oncology during the fourth quarter worth approximately $164,000. Creative Planning boosted its position in ZIOPHARM Oncology by 289.3% in the first quarter. Creative Planning now owns 57,863 shares of the biotechnology company’s stock worth $367,000 after buying an additional 43,000 shares during the last quarter. Finally, Janney Montgomery Scott LLC boosted its position in ZIOPHARM Oncology by 6.2% in the first quarter. Janney Montgomery Scott LLC now owns 266,366 shares of the biotechnology company’s stock worth $1,689,000 after buying an additional 15,610 shares during the last quarter. 38.05% of the stock is currently owned by institutional investors and hedge funds.
Shares of ZIOPHARM Oncology Inc (ZIOP) opened at 5.75 on Friday. ZIOPHARM Oncology Inc has a 52 week low of $4.55 and a 52 week high of $7.88. The company’s market cap is $751.53 million. The company has a 50 day moving average of $5.92 and a 200-day moving average of $6.34.
ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its earnings results on Monday, May 1st. The biotechnology company reported ($0.15) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by $0.03. The firm had revenue of $1.60 million during the quarter, compared to the consensus estimate of $1.71 million. ZIOPHARM Oncology’s revenue for the quarter was down 18.8% compared to the same quarter last year. On average, equities research analysts expect that ZIOPHARM Oncology Inc will post ($0.58) earnings per share for the current fiscal year.
WARNING: This report was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://stocknewstimes.com/2017/07/29/alliancebernstein-l-p-has-1233000-stake-in-ziopharm-oncology-inc-nasdaqziop.html.
ZIOP has been the topic of a number of recent research reports. Zacks Investment Research cut shares of ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research report on Thursday, April 6th. HC Wainwright initiated coverage on shares of ZIOPHARM Oncology in a research report on Thursday, June 1st. They set a “buy” rating and a $9.50 target price on the stock. Finally, ValuEngine raised shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $13.00.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.
